Yuhan, which had a high dependence on sales for imported drugs, has recently been speeding up with the commercialization of new drugs such as Lazertinib and IMD. In particular, Yuhan refrains from entrusting or entrusting developing products and is building market competitiveness with its own products.

The MFDS approved "Raboni-D," Yuhan's combined osteoporosis IMD, on the 17th. It is a combination drug of Raloxifene HCl, an existing osteoporosis treatment drug, and Cholecalciferol Concentrated Powder, known as a vitamin D.

There are already six products, including Hanmi Pharmaceutical's "Rabone D" and Alvogen Korea's "Ebistrar Plus," that combine the two ingredients. However it is evalua